# CalciMedica (CALC) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CALC
## Company Profile
- Ticker: CALC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 1.54 USD
- Market cap: 12646323.8155 USD
- Last updated: 2026-10-05
## Business Overview
CalciMedica is a biotechnology company focused on calcium-channel biology and inflammatory disease. Its story centers on using a targeted mechanism to address severe immune-mediated conditions.
## Why The Stock Is Moving

As of Oct 5, 2026, CALC closed down 3.75% at $1.54. No new same-company headline was identified in the current news window.

## Geographic Base

CalciMedica is headquartered in the United States and listed on NASDAQ. It sits in small-cap immunology biotechnology.

## Business Model

The company depends on clinical validation, translational confidence, and capital discipline while it advances a focused pipeline. Investors watch early data and safety.

## Landscape Position

CalciMedica occupies a niche inflammation pathway position within biotech. The stock is driven by whether its biology can create a real clinical signal.

## Future Catalysts

- CalciMedica’s catalysts are calcium-signaling inflammation programs and any clinical update that clarifies whether the company can still build a viable development story. The next step matters because the story remains early.

## Recent News
- 2023-08-10 20:05 EST — [CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates](https://biopharmsignal.com/news/CALC/calcimedica-reports-second-quarter-2023-financial-results-and-provides-clinical--4dd19713) — Source: CalciMedica
- 2023-08-09 11:30 EST — [CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)](https://biopharmsignal.com/news/CALC/calcimedica-announces-first-patient-enrolled-in-international-expansion-of-carpo-a2f7e7fc) — Source: CalciMedica
- 2023-06-12 11:30 EST — [CalciMedica Announces Relisting on Nasdaq](https://biopharmsignal.com/news/CALC/calcimedica-announces-relisting-on-nasdaq-956a981d) — Source: CalciMedica
- 2023-06-06 11:30 EST — [CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)](https://biopharmsignal.com/news/CALC/calcimedica-announces-publication-of-preclinical-data-in-journal-of-clinical-inv-4763f290) — Source: CalciMedica
- 2023-05-23 11:30 EST — [CalciMedica Expands Executive Team with New Appointments](https://biopharmsignal.com/news/CALC/calcimedica-expands-executive-team-with-new-appointments-8dcb8eb8) — Source: CalciMedica